United-guardian ( (UG) ) has released its Q2 earnings. Here is a breakdown of the information United-guardian presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
United-Guardian, Inc., a manufacturer in the cosmetics, pharmaceuticals, medical lubricants, and sexual wellness sectors, has released its financial results for the second quarter of 2025, showing mixed performance across its product lines.
The company’s second-quarter net sales fell to $2.84 million from $3.39 million in the same period last year, while net income decreased to $626,826 from $956,225. However, compared to the first quarter of 2025, both net sales and net income saw increases of 14% and 12%, respectively. For the first half of 2025, net sales were down to $5.32 million from $6.65 million in 2024, and net income dropped to $1.19 million from $1.88 million.
The company experienced growth in its pharmaceuticals and medical lubricants segments, with sales increasing by 11% and 12%, respectively, in the first half of 2025 compared to the previous year. However, this growth was offset by a decline in cosmetic ingredient sales, primarily due to reduced purchases by its largest distributor, Ashland Specialty Ingredients, amid softer demand in Asia and an inventory overstock situation.
Looking ahead, United-Guardian is optimistic about resolving the overstock issue and improving cosmetic sales in the latter half of the year. Additionally, the company is working on expanding the inclusion of its key pharmaceutical product, Renacidin, in more drug formularies, which could significantly boost future sales if successful.